Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials

Humanized anti–interleukin-6 receptor antibody treatment of multicentric Castleman disease

Norihiro Nishimoto, Yuzuru Kanakura, Katsuyuki Aozasa et al. · Blood · 2005 · 745 citations · Full text

International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease

David C. Fajgenbaum, Thomas S. Uldrick, Adam Bagg et al. · Blood · 2017 · 590 citations · Full text

Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial

Frits van Rhee, Raymond Wong, Nikhil C. Munshi et al. · The Lancet Oncology · 2014 · 420 citations

Medicine, Multicentric Castleman, Scleroderma

International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease

Frits van Rhee, Peter M. Voorhees, Angela Dispenzieri et al. · Blood · 2018 · 394 citations · Full text

Epidemiology and management of hyperlipidemia.

Samantha Karr · PubMed · 2017 · 368 citations

Hyperlipidemia, Preventive Cardiology, United States +20